The group's principal activity is to engage in the research and development of applications utilizing modified substance p, a naturally occurring immunomodulator. Derived from homeostatic substance p, the group has named its proprietary compound 'homspera'. The group's main focus is in the development of several applications for use in improving pulmonary function and stimulating the immune system. On 20-Jul-2003, the group acquired immuneregen biosciences inc.
